Departments of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Department of Clinical Research, University of Basel, Basel, Switzerland.
Pituitary. 2022 Aug;25(4):636-644. doi: 10.1007/s11102-022-01240-0. Epub 2022 Jun 20.
Non-osmotic stimulation tests using glucagon, arginine, or macimorelin were recently evaluated for their ability to assess posterior pituitary function. Glucagon and arginine, but not macimorelin, stimulated copeptin secretion (a surrogate marker of vasopressin) and, therefore, provide novel tests to assess the posterior pituitary. The exact underlying mechanism behind their stimulatory effect remains elusive.
This analysis combined data from three diagnostic studies conducted at the University Hospital Basel, Switzerland. In total, 80 healthy adults underwent the glucagon (n = 22), arginine (n = 30), or macimorelin (n = 28) stimulation tests. The primary objective was to investigate glucose course upon glucagon, arginine, and macimorelin stimulation tests and its effect on plasma copeptin release.
Upon glucagon stimulation, the median [IQR] glucose level at baseline was 5.0 [4.6, 5.2] mmol/l, peaked at 8.1 [7.2, 9.4] mmol/l after 30 min and decreased to a minimum of 3.8 [3.5, 4.5] mmol/l after 120 min. The median copeptin increase upon glucagon stimulation was 7.7 [2.6, 28.0] pmol/l. Upon arginine, the glucose level at baseline was 4.9 [4.8, 5.5] mmol/l, peaked at 6.0 [5.2, 6.4] mmol/l after 30 min and decreased to a minimum of 4.3 [3.8, 4.8] mmol/l after 60 min. The median copeptin increase upon arginine stimulation was 4.5 [2.9, 7.5] pmol/l. Upon macimorelin, glucose levels showed no notable dynamics over the 120 min, and no major change in copeptin was observed. In the pooled dataset, a decrease in glucose levels was significantly correlated with copeptin increase (ρ = 0.53, p < 0.01).
A similar course in plasma glucose was observed in the copeptin-stimulating test, i.e., after glucagon and arginine, while macimorelin had no effect on glucose and copeptin levels. We hypothesize that a drop in glucose levels observed upon glucagon and arginine might stimulate copeptin.
使用胰高血糖素、精氨酸或麦角隐亭对非渗透刺激试验进行了最近的评估,以评估其评估垂体后叶功能的能力。胰高血糖素和精氨酸,但不是麦角隐亭,刺激 copeptin 分泌(血管加压素的替代标志物),因此提供了评估垂体后叶的新测试。其刺激作用的确切潜在机制仍不清楚。
本分析结合了瑞士巴塞尔大学医院进行的三项诊断研究的数据。总共 80 名健康成年人接受了胰高血糖素(n=22)、精氨酸(n=30)或麦角隐亭(n=28)刺激试验。主要目的是研究胰高血糖素、精氨酸和麦角隐亭刺激试验时的血糖变化及其对血浆 copeptin 释放的影响。
在胰高血糖素刺激下,基线时的中位[IQR]血糖水平为 5.0[4.6,5.2]mmol/l,30 分钟后峰值为 8.1[7.2,9.4]mmol/l,120 分钟后降至最低 3.8[3.5,4.5]mmol/l。胰高血糖素刺激下的中位 copeptin 升高为 7.7[2.6,28.0]pmol/l。在精氨酸刺激下,基线时的血糖水平为 4.9[4.8,5.5]mmol/l,30 分钟后峰值为 6.0[5.2,6.4]mmol/l,60 分钟后降至最低 4.3[3.8,4.8]mmol/l。精氨酸刺激下的中位 copeptin 升高为 4.5[2.9,7.5]pmol/l。在麦角隐亭刺激下,血糖水平在 120 分钟内没有明显变化,copeptin 也没有明显变化。在汇总数据集,血糖水平的降低与 copeptin 升高显著相关(ρ=0.53,p<0.01)。
在促 copeptin 试验中观察到类似的血浆葡萄糖变化,即胰高血糖素和精氨酸后,而麦角隐亭对葡萄糖和 copeptin 水平没有影响。我们假设,在胰高血糖素和精氨酸刺激下观察到的血糖水平下降可能会刺激 copeptin。